Shire is a biotechnology company that researches, develops, licenses, manufactures, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The Company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Shire markets its products through wholesalers, distributors, and various pharmacies.
Jersey, JE
Size (employees)
23,906 (est)
Shire was founded in 1986 and is headquartered in Jersey, JE
Report incorrect company information

Key People/Management at Shire

Flemming Ornskov

Flemming Ornskov

Chief Executive Officer
Bill Mordan

Bill Mordan

General Counsel and Company Secretary
Joanne Cordeiro

Joanne Cordeiro

Chief Human Resources Officer
Perry Sternberg

Perry Sternberg

Head of US Commercial
Kim Stratton

Kim Stratton

Head of International Commercial
BSCHE Matt Walker

BSCHE Matt Walker

Head of Technical Operations

Shire Office Locations

Shire has offices in Singapore, Dublin, Jersey, Lexington and in 37 other locations
Jersey, JE (HQ)
No. 99854, 22 Grenville Street, St Helier
São Paulo, BR
Av. das Nações Unidas, 14.171, 5o andar
Saint-Laurent, CA
2250 Alfred-Nobel Blvd, Suite 500
Boulogne Billancourt, FR
88, rue du Dôme
Berlin, DE
Friedrichstraße 149
Dublin, IE
5 Riverwalk
Show all (41)
Report incorrect company information

Shire Financials and Metrics

Shire Financials

Shire's revenue was reported to be $15.16 b in FY, 2017 which is a 39.3% increase from the previous period.

Revenue (FY, 2017)

15.2 b

Revenue growth (FY, 2016 - FY, 2017), %


Gross profit (FY, 2017)

10.5 b

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

4.3 b

EBIT (FY, 2017)

2.5 b

Market capitalization (27-Oct-2017)

42.4 b

Closing share price (27-Oct-2017)


Cash (31-Dec-2017)

472.4 m


61.4 b
Shire's current market capitalization is $42.4 b.
GBPFY, 2015FY, 2016FY, 2017


6.4 b10.9 b15.2 b

Revenue growth, %


Cost of goods sold

969 m3.8 b4.7 b

Gross profit

5.4 b7.1 b10.5 b
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


1.5 b1.6 b1.7 b1.7 b2.4 b3.5 b3.6 b3.7 b3.5 b

Cost of goods sold

227.8 m228 m262.7 m248.6 m778.1 m1.7 b1.3 b1.1 b1 b

Gross profit

1.3 b1.3 b1.4 b1.5 b1.7 b1.7 b2.2 b2.6 b2.5 b

Gross profit Margin, %

GBPFY, 2015FY, 2016FY, 2017


135.5 m528.8 m472.4 m

Accounts Receivable

1.2 b2.6 b3 b

Prepaid Expenses

197.4 m806.3 m795.3 m


635.4 m3.6 b3.3 b
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


74.3 m64 m44.9 m69 m693.4 m728.6 m369 m263.7 m209.3 m

Accounts Receivable

1.1 b1.1 b1.3 b1.3 b2.4 b2.6 b2.6 b2.8 b2.8 b

Prepaid Expenses

216.6 m221.6 m215 m314.4 m733.6 m665.3 m787.2 m778.5 m779.9 m


588.7 m632.8 m608.9 m680 m5.8 b4.9 b3.3 b3.3 b3.4 b
GBPFY, 2015FY, 2016FY, 2017

Net Income

1.3 b327.4 m4.3 b

Depreciation and Amortization

637.2 m1.5 b2.3 b


(63.2 m)(255.8 m)(145.1 m)

Accounts Payable

109.2 m621.6 m(526.8 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

410.4 m570 m1 b419 m256.9 m(129.9 m)375 m615.3 m1.2 b

Depreciation and Amortization

120.6 m291.8 m457.4 m168.9 m429.8 m877.8 m486.9 m1 b1.6 b


(22 m)(37.4 m)(21.7 m)(32.2 m)(116.4 m)(228 m)(151.8 m)(171.6 m)(245.2 m)

Accounts Payable

77.5 m(39.8 m)56.5 m(154.6 m)342.7 m315.2 m(671.5 m)(445.1 m)(557.8 m)
USDY, 2017


25 x


14.4 x


634.2 k


0.5 x


0.3 x

Financial Leverage

1.9 x
Show all financial metrics

Shire Operating Metrics

FY, 2014FY, 2015FY, 2016FY, 2017

Phase I Trials Products

7 6 6 7

Phase II Trials Products

11 6 10 10

Phase III Trials Products

7 14 17 15

Phase Approved

2 3 4 7
Show all operating metrics

Shire Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Baxalta January 11, 2016$32 b
Dyax November 02, 2015$5.90 b
Foresight Biotherapeutics August 03, 2015$300 m
Meritage Pharma February 24, 2015$245 m
NPS Pharmaceuticals, Inc. January 11, 2015$5.20 b
Lumena Pharmaceuticals May 13, 2014$260 m
Fibrotech Therapeutics May 02, 2014$75 m
ViroPharma Incorporated November 11, 2013$4.20 b
SARcode Bioscience March 25, 2013$160 m
Premacure March 12, 2013
Show more
Report incorrect company information

Shire News and Updates

After some Thursday drama, Shire weighs Takeda's fourth buyout bid at $61B-plus

The third time wasn’t the charm for Takeda in its attempts to swallow Shire—but the fourth time might be. Friday, the Dublin drugmaker said Japan’s largest pharma offered £47 per share, almost half of that in cash, or about £44 billion ($61.6 billion).

Just what the doctor ordered? Takeda has upped its offer for Shire again

Japanese pharmaceutical company Takeda today made an improved offer for Shire, after its £43bn takeover bid was rejected. The company is now willing to pay £47 per share, of which £21 would be cash and £26 new Takeda shares. This represents a seven per cent increase on the original proposal of…

FiercePharmaAsia—Tussle for Shire, Hanmi’s EGFR bail, Grail’s $1B pre-IPO round

Allergan was in and out of pursuit for Shire as Takeda's third offer was rejected, Hanmi ditched its would-be Tagrisso rival olmutinib, Grail is reportedly considering a $1 billion financing before its expected Hong Kong IPO, and more.

Japan's Takeda sweetens $62 billion Shire offer

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals.

Shire Pandemonium, Aluminum Glut, ZTE Fallout: CEO Daily for April 20, 2018

Must-read business news, delivered every morning.

Takeda's considering turning up the heat on its bid for Shire (TKPYY, SHPG)

Takeda is considering a new bid for Adderall drugmaker Shire, raising the share price to 47 British pounds (about $66) per share up from 46.50 per share (about $65), Bloomberg reported Friday. Shire has already turned down three offers from the Japanese pharmaceutical company, the last of which wa…
Show more
Report incorrect company information